Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status

被引:0
作者
Makoto Ohno
Yoshitaka Narita
Yasuji Miyakita
Yoshiko Okita
Yuko Matsushita
Akihiko Yoshida
Shintaro Fukushima
Koichi Ichimura
Takamasa Kayama
Soichiro Shibui
机构
[1] National Cancer Center Hospital,Department of Neurosurgery and Neuro
[2] National Cancer Center Hospital,Oncology
[3] National Cancer Center Research Institute,Department of Pathology and Clinical Laboratories
来源
Brain Tumor Pathology | 2012年 / 29卷
关键词
Astrocytoma; Oligodendroglioma; Glioblastoma; IDH; Malignant progression;
D O I
暂无
中图分类号
学科分类号
摘要
The impact of isocitrate dehydrogenase (IDH1/2) mutations on the malignant progression of gliomas was investigated by comparing the histopathological features of 53 grade II and III gliomas after recurrence according to the IDH1/2 status. We identified IDH1/2 mutations in 44.4 % (16 of 36) of astrocytic tumors and 70.6 % (12 of 17) of oligodendroglial tumors. Histopathological malignant progression was observed in 68.8 % (11 in 16) and 55 % (11 in 20) of astrocytic tumors with and without IDH1/2 mutations, respectively. There were 8 secondary glioblastomas (GBM) that had progressed from 5 diffuse astrocytomas (DA) and 3 anaplastic astrocytomas (AA) with IDH1/2 mutations. Seven secondary GBMs were derived from 3 DAs and 4 AAs with wild-type IDH1/2. Malignant progression was observed in 47.1 % (8 of 17) of oligodendroglial tumors. All 12 oligodendroglial tumors with IDH1/2 mutations remained as such without progressing to GBM, whereas 3 of the 5 oligodendroglial tumors without IDH1/2 mutations progressed to GBM at recurrence. In conclusion, grade II and III gliomas developed to more malignant histological types, irrespective of the IDH1/2 mutation status, and the monitoring of the IDH1/2 status could be of value to predict the development of GBM in patients with oligodendroglial tumors.
引用
收藏
页码:183 / 191
页数:8
相关论文
共 50 条
[41]   IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group [J].
Pollack, Ian F. ;
Hamilton, Ronald L. ;
Sobol, Robert W. ;
Nikiforova, Marina N. ;
Lyons-Weiler, Maureen A. ;
LaFramboise, William A. ;
Burger, Peter C. ;
Brat, Daniel J. ;
Rosenblum, Marc K. ;
Holmes, Emiko J. ;
Zhou, Tianni ;
Jakacki, Regina I. .
CHILDS NERVOUS SYSTEM, 2011, 27 (01) :87-94
[42]   IDH1/2 Mutation and MGMT Promoter Methylation - the Relevant Survival Predictors in Czech Patients with Brain Gliomas [J].
Kramar, F. ;
Minarik, M. ;
Benesova, L. ;
Halkova, T. ;
Netuka, D. ;
Bradac, O. ;
Benes, V. .
FOLIA BIOLOGICA, 2016, 62 (05) :194-202
[43]   The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas [J].
Wang, Hao-Yuan ;
Tang, Kai ;
Liang, Ting-Yu ;
Zhang, Wei-Zhong ;
Li, Ji-Ye ;
Wang, Wen ;
Hu, Hui-Min ;
Li, Ming-Yang ;
Wang, Hui-Qing ;
He, Xiao-Zheng ;
Zhu, Zhi-Yuan ;
Liu, Yan-Wei ;
Zhang, Shi-Zhong .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
[44]   Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status [J].
Hu, Yue ;
Zhang, Ni ;
Yu, Min Hao ;
Zhou, Xue Jun ;
Ge, Min ;
Shen, Dan Dan ;
Hua, Ye ;
Shi, Jin Long ;
Jia, Zhong Zheng .
EUROPEAN JOURNAL OF RADIOLOGY, 2020, 131
[45]   Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas [J].
Christian Hartmann ;
Bettina Hentschel ;
Wolfgang Wick ;
David Capper ;
Jörg Felsberg ;
Matthias Simon ;
Manfred Westphal ;
Gabriele Schackert ;
Richard Meyermann ;
Torsten Pietsch ;
Guido Reifenberger ;
Michael Weller ;
Markus Loeffler ;
Andreas von Deimling .
Acta Neuropathologica, 2010, 120 :707-718
[46]   Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas [J].
Hartmann, Christian ;
Hentschel, Bettina ;
Wick, Wolfgang ;
Capper, David ;
Felsberg, Joerg ;
Simon, Matthias ;
Westphal, Manfred ;
Schackert, Gabriele ;
Meyermann, Richard ;
Pietsch, Torsten ;
Reifenberger, Guido ;
Weller, Michael ;
Loeffler, Markus ;
von Deimling, Andreas .
ACTA NEUROPATHOLOGICA, 2010, 120 (06) :707-718
[47]   IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas [J].
Leeper, Heather E. ;
Caron, Alissa A. ;
Decker, Paul A. ;
Jenkins, Robert B. ;
Lachance, DanielH. ;
Giannini, Caterina .
ONCOTARGET, 2015, 6 (30) :30295-30305
[48]   Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas [J].
Zhang, Jie ;
Yang, Jian-hui ;
Quan, Jia ;
Kang, Xing ;
Wang, Hui-juan ;
Dai, Peng-gao .
TUMOR BIOLOGY, 2016, 37 (10) :13571-13579
[49]   Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis [J].
Jungk, Christine ;
Scherer, Moritz ;
Mock, Andreas ;
Capper, David ;
Radbruch, Alexander ;
von Deimling, Andreas ;
Bendszus, Martin ;
Herold-Mende, Christel ;
Unterberg, Andreas .
JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (02) :319-328
[50]   Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma [J].
Celik, Serkan ;
Oven, Bala Basak ;
Demir, Mustafa Kemal ;
Yilmaz, Enis Cagatay ;
Kanan, Duaa ;
Ozdamarlar, Umut ;
Emirzeoglu, Levent ;
Yapicier, O. Ozlem ;
Kilic, Turker .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2021, 207